XVIVO — Xvivo Perfusion AB Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapFalling Star

Annual income statement for Xvivo Perfusion AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

	C2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	180	258	415	598	822
Cost of Revenue
Gross Profit	130	188	297	445	616
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	226	277	409	524	670
Operating Profit	-45.7	-18.5	6.41	73.2	153
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-57.3	6.67	22.3	94.5	200
Provision for Income Taxes
Net Income After Taxes	-43.7	8.15	18.4	91.8	172
Net Income Before Extraordinary Items
Net Income	-43.7	8.15	18.4	91.8	172
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-43.7	8.15	18.4	91.8	172
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.61	0.283	0.852	2.11	4.45
Dividends per Share